Stephan Lüders

Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention

Joachim Schrader, Stephan Lüders, Anke Kulschewski et al. · Stroke · 2005 · 763 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

The ACCESS Study

Joachim Schrader, Stephan Lüders, Anke Kulschewski et al. · Stroke · 2003 · 650 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +17

The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial

Else Charlotte Sandset, Philip M. Bath, Gudrun Boysen et al. · The Lancet · 2011 · 535 citations

Medicine, Cardiology, Pharmacology +13

The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League

Stephan Lüders, Joachim Schrader, Jürgen Berger et al. · Journal of Hypertension · 2008 · 230 citations

Medicine, Pharmacology, Pharmacotherapy +17

Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*

Joachim Schrader, Stephan Lüders, Anke Kulschewski et al. · Journal of Hypertension · 2006 · 98 citations

Medicine, Nephrology, Pharmacotherapy +13